Selenium binding protein 1 in ovarian cancer
Selenium binding protein 1 in ovarian cancer
复制标题
DOI：
10.1002/ijc.21671
复制
发表时间：
2006-05-15
影响因子：
6.4
通讯作者：
Ng, SW
中科院分区：
文献类型：
--
作者：
Huang, KC;Park, DC;Ng, SW
通过膜蛋白质组分析，硒结合蛋白 I (SELENBP1) 被确定为卵巢癌细胞中下调最显着的蛋白。采用免疫组织化学方法分析 4 例正常卵巢、8 例良性卵巢肿瘤、12 例交界性卵巢肿瘤和 141 例浸润性卵巢癌中 SELENBP1 的表达水平。 SELENBP1 表达在 87% 的浸润性卵巢癌病例中降低 (122/141)，并且在交界性肿瘤和浸润性癌中显着降低 (p < 0.001)。 141 个浸润性癌组织中的 Cox 多变量分析表明，SELENBP1 表达评分是卵巢癌不良预后的潜在预后指标（风险比 [HR]，2.18；95% CI = L22-190；p = 0.009）。硒可以破坏雄激素途径，这与调节 SELENBP1 表达有关。我们研究了硒和雄激素对正常人卵巢表面上皮 (HOSE) 细胞和癌细胞的影响。有趣的是，在正常 HOSE 细胞中，雄激素降低了 SELENBP1 mRNA 和蛋白质水平，而硒处理则升高了 SELENBP1 mRNA 和蛋白质水平，而在卵巢癌细胞系中观察到相反的反应。这些结果表明，恶性卵巢癌中SELENBP1表达的变化是硒/雄激素途径异常的指标，并可能揭示卵巢癌的预后信息。 (c) 2005 年 Wiley-Liss, Inc.
Selenium binding protein I (SELENBP1) was identified to be the most significantly down-regulated protein in ovarian cancer cells by a membrane proteome profiling analysis. SELENBP1 expression levels in 4 normal ovaries, 8 benign ovarian tumors, 12 borderline ovarian tumors and 141 invasive ovarian cancers were analyzed with immunohistochemical assay. SELENBP1 expression was reduced in 87% cases of invasive ovarian cancer (122/141) and was significantly reduced in borderline tumors and invasive cancers (p < 0.001). Cox multivariate analysis within the 141 invasive cancer tissues showed that SELENBP1 expression score was a potential prognostic indicator for unfavorable prognosis of ovarian cancer (hazard ratio [HR], 2.18; 95% CI = L22-190; p = 0.009). Selenium can disrupt the androgen pathway, which has been implicated in modulating SELENBP1 expression. We investigated the effects of selenium and androgen on normal human ovarian surrace epithelial (HOSE) cells and cancer cells. Interestingly, SELENBP1 mRNA and protein levels were reduced by androgen and elevated by selenium treatment in the normal HOSE cells, whereas reversed responses were observed in the ovarian cancer cell lines. These results suggest that changes of SELENBP1 expression in malignant ovarian cancer are an indicator of aberration of selenium/androgen pathways and may reveal prognostic information of ovarian cancer. (c) 2005 Wiley-Liss, Inc.